Anti-VEGF Receptor 2 antibody [mV1001.3m-h] (ab42228)

Overview

  • Product nameAnti-VEGF Receptor 2 antibody [mV1001.3m-h]
    See all VEGF Receptor 2 primary antibodies
  • Description
    Mouse monoclonal [mV1001.3m-h] to VEGF Receptor 2
  • Tested applicationsSandwich ELISA, WB, IP, Functional Studiesmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Purified fragment, corresponding to N terminal amino acids 30-200 of Human VEGF Receptor 2

  • Positive control
    • Human Umbilical Vein Endothelial Cells (HUVECs).

Applications

Our Abpromise guarantee covers the use of ab42228 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Sandwich ELISA Use a concentration of 5 µg/ml. Can be paired for Sandwich ELISA with Rabbit polyclonal to VEGF Receptor 2 (ab11939). For sandwich ELISA, use this antibody as Capture at 5µg/ml with ab11939 as Detection.
WB Use at an assay dependent dilution. Predicted molecular weight: 151 kDa.
IP Use at an assay dependent dilution.
Functional Studies Use a concentration of 5 - 25 µg/ml. This antibody can induce VEGF Receptor 2 tyrosine phosphorylation in Human Umbilical Vein Endothelial Cells (HUVECs).

Target

  • FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
  • Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
  • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • CD309 antibody
    • CD309 antigen antibody
    • EC 2.7.10.1 antibody
    • Fetal liver kinase 1 antibody
    • FLK-1 antibody
    • FLK1 antibody
    • FLK1, mouse, homolog of antibody
    • KDR antibody
    • Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody
    • Kinase insert domain receptor antibody
    • KRD1 antibody
    • Ly73 antibody
    • Protein tyrosine kinase receptor FLK1 antibody
    • Protein-tyrosine kinase receptor flk-1 antibody
    • soluble VEGFR2 antibody
    • Tyrosine kinase growth factor receptor antibody
    • Vascular endothelial growth factor receptor 2 antibody
    • VEGFR 2 antibody
    • VEGFR antibody
    • VEGFR-2 antibody
    • VEGFR2 antibody
    • VGFR2_HUMAN antibody
    see all

Anti-VEGF Receptor 2 antibody [mV1001.3m-h] images

Protocols

References for Anti-VEGF Receptor 2 antibody [mV1001.3m-h] (ab42228)

This product has been referenced in:
  • Ptaszynska MM  et al. Positive Feedback between Vascular Endothelial Growth Factor-A and Autotaxin in Ovarian Cancer Cells. Mol Cancer Res 6:352-63 (2008). Read more (PubMed: 18337445) »

See 1 Publication for this product

Product Wall

Thank you for your reply. I have now returned to the office an hope I can help further with your enquiry.

I can now confirm that of the antibodies we have directed against VEGF Receptor 2 (that are not raised in rabbit), most likely to react w...

Read More



Reviewing the correspondence on this enquiry so far, I notice xxxx has selected some antibodies not raised in rabbit and has been in contact with the originators to obtain further information regarding the immunogen sequence so we can work o...

Read More

Thank you for contacting us.

I have checked with the lab and they did not try using lysate for the activation assay but are in agreement that this would probably not work due to the presence of detergents and lysis buffer.

I hope t...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"